Sréter L, Kárteszi M, Fehér J, Lutz D
2nd Department of Internal Medicine, Semmelweis University Medical School, Budapest.
Acta Med Hung. 1988;45(3-4):323-8.
Serum procollagen-III-peptide (P-III-P) and laminin P 1 (LP1) concentrations were measured in 24 patients with various chronic myeloproliferative diseases, viz., essential thrombocythaemia (ET), chronic myelogenous leukaemia (CML) and myelofibrosis (MF). The highest P-III-P values were found in myelofibrosis. As compared to the controls, the serum laminin concentration was higher in all there groups of patients. No significant difference was found between the groups of patients. After three months of alpha-IFN therapy the P-III-P values became significantly higher, the laminin concentration slightly decreased in all investigated patients. Longitudinal follow-up myeloproliferative patients should be carried out in order to prove whether P-III-P and laminin determinations provide a useful test to monitor the progression of the disease and the effect of the therapy.
对24例患有各种慢性骨髓增殖性疾病的患者，即原发性血小板增多症（ET）、慢性粒细胞白血病（CML）和骨髓纤维化（MF），测定了血清Ⅲ型前胶原肽（P-III-P）和层粘连蛋白P1（LP1）的浓度。骨髓纤维化患者的P-III-P值最高。与对照组相比，所有这三组患者的血清层粘连蛋白浓度均较高。各患者组之间未发现显著差异。α-干扰素治疗三个月后，所有受调查患者的P-III-P值显著升高，层粘连蛋白浓度略有下降。应进行骨髓增殖性患者的纵向随访，以证实P-III-P和层粘连蛋白测定是否能为监测疾病进展和治疗效果提供有用的检测方法。
